Current treatment strategies of the German Hodgkin Study Group (GHSG)

European Journal of Haematology, Supplement

Volumn 75, Issue 66, 2005, Pages 125-134

  Klimm, Beate ^a   Diehl, Volker ^a   Pfistner, Beate ^a   Engert, Andreas ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Chemotherapy; Clinical trials; Experimental treatment; Hodgkin's lymphoma; Radiotherapy

Indexed keywords

ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; BLEOMYCIN; CANCER VACCINE; CHLORMETHINE DERIVATIVE; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IMMUNOTOXIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD30; PREDNISONE; PROCARBAZINE; RITUXIMAB; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; GERMANY; HODGKIN DISEASE; HUMAN; INFERTILITY; LONG TERM CARE; LUNG TOXICITY; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; SECOND CANCER; SEXUAL DYSFUNCTION; TREATMENT FAILURE; TREATMENT OUTCOME; FEMALE; MALE; MULTIMODALITY CANCER THERAPY; RADIOTHERAPY; RECURRENT DISEASE; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; GERMANY; HODGKIN DISEASE; HUMANS; MALE; RADIOTHERAPY; RECURRENCE;

EID: 21044457666     PISSN: 09024506     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (63)

1. LONGO DL, YOUNG RC, WESLEY M, et al. Twenty years of MOPP chemotherapy for Hodgkin's disease. J Clin Oncol 1986;4:1295-1306.
2. BONADONNA G, ZUCALI R, MONFARDINI S, et al. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboximide versus MOPP. Cancer 1975;36:252-259.
3. NG AK, BERNARDO MV, WELLER E, et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 2002;100:1989-1996.
4. BHATIA S, YASUI Y, ROBISON LL, et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol 2003;21:4386-4394.
5. VAN LEEUWEN FE, KLOKMAN WJ, STOVALL M, et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 2003;95:971-980.
6. CANELLOS GP, NIEDZWIECKI D. Long-term follow-up of Hodgkin's disease trial. N Engl J Med 2002;346:1417-1418.
7. CARDE P, HAGENBEEK A, HAYAT M, et al. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1993;11:2258-2272.
8. CARBONE PP, KAPLAN HS, MUSSHOFF K, et al. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971;31:1860-1861.
9. LISTER T, CROWTHER D, SUTCLIFFE S, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989;7:1630-1636.
10. DIEHL V, STEIN H, HUMMEL M, ZOLLINGER R, CONNORS JM. Hodgkin's Lymphoma: Biology and Treatment Strategies for Primary, Refractory, and Relapsed Disease. Hematology (Am Soc Hematol Educ Program) 2003;225-472.
11. HASENCLEVER D, DIEHL V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998;339:1506-1514.
12. HORWICH A, SPECHT L, ASHLEY S. Survival analysis of patients with clinical stages I or II Hodgkin's disease who have relapsed after initial treatment with radiotherapy alone. Eur J Cancer 1997;33:848-853.
13. SPECHT L, GRAY RG, CLARKE MJ, et al. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group. J Clin Oncol 1998;16:830-843.
14. HANCOCK SL, TUCKER MA, HOPPE RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 1993;270:1949-1955.
15. DUBRAY B, HENRY-AMAR M, MEERWALDT JH, et al. Radiation-induced lung damage after thoracic irradiation for Hodgkin's disease: the role of fractionation. Radiother Oncol 1995;36:211-217.
16. PRESS OW, LEBLANC M, LICHTER AS, et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J Clin Oncol 2001;19:4238-4244.
17. HORNING SJ, HOPPE RT, BRESLIN S, et al. Very brief (8 week) chemotherapy (CT) and low dose (30 Gy) radiotherapy (RT) for limited stage Hodgkin's disease (HD): preliminary results of the Stanford-Kaiser G4 Study of Stanford V + RT. Blood 1999;94:1717a.
18. BONFANTE V, VIVIANI S, DEVIZZ IL, et al. Ten-year experience with ABVD plus radiotherapy: subtotal nodal (STNI) versus involved field (IFRT) in early stage Hodgkin's disease. Proc ACSO 2001;20:281a.
19. RAEMAEKERS J, KLUIN-NELEMANS H, TEODOROVIC I, et al. The achievements of the EORTC Lymphoma Group. European Organisation for Research and Treatment of Cancer. Eur J Cancer 2002;38:S107-S113.
20. SIEBER M, FRANKLIN J, TESCH H, et al. Two cycles ABVD plus extended field radiotherapy is superior to radiotherapy alone in early stage Hodgkin's disease: results of the German Hodgkin's Lymphoma Study Group (GHSG) Trial HD7. Blood 2002;100:341a.
21. DIEHL V, BRILLANT C, ENGERT A, et al. Reduction of combined modality treatment intensity in early stage Hodgkin's lymhoma: interim analysis of the HD10 trial of the GHSG. Eur J Hematol 2004;73(Suppl. 65):37.E03.
22. ZITTOUN R, AUDEBERT A, HOERNI B, et al. Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin's disease. J Clin Oncol 1985;3:207-214.
23. FERME C, EGHBALI H, HABENBEEK A, et al. MOPP/ABV (M/A) hybrid and irradiation in unfavorable supradiaphragmatic clinical stages I-II HD: comparison of three treatment modalities, preliminary results of the EORTC-GELA H8-U randomized trial in 995 patients. Blood 2000;96:576a.
24. ENGERT A, SCHILLER P, JOSTING A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's Lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003;21:3601-3608.
25. CONNORS JM, KLIMO P, ADAMS G, et al. Treatment of advanced Hodgkin's disease with chemotherapy - comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1997;15:1638-1645.
26. DUGGAN DB, PETRONI GR, JOHNSON JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 2003;21:607-614.
27. SIEBER M, TESCH H, PFISTNER B, et al. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5. J Clin Oncol 2002;20:476-484.
28. CANELLOS GP, ANDERSON JR, PROPERT KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478-1484.
29. DIEHL V, BRILLANT C, ENGERT A, et al. Intensification of chemotherapy and concomitant reduction of radiotherapy dose in intermediate stage Hodgkin's lymphoma: results of the fourth interim analysis of the HD 11 trial of the GHSG. Eur J Hematol 2004;73(Suppl. 65):37.E02.
30. DIEHL V, FRANKLIN J, PFREUNDSCHUH M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003;348:2386-2395.
31. BONADONNA G, VALAGUSSA P, SANTORO A. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results. Ann Intern Med 1986;104:739-746.
32. SANTORO J, BONADONNA G, VALAGUSSA P, et al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 1987;5:27-37.
33. SIEBER M, TESCH H, PFISTNER B, et al. Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's Lymphoma Study Group HD6 trial. Ann Oncol 2004;15:276-282.
34. HORNING SJ, HOPPE RT, BRESLIN S, et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 2002;20:630-637.
35. CHISESI T, FEDERICO M, LEVIS A, et al. ABVD versus Stanford V versus MEC in unfavourable Hodgkin's lymphoma: results of a randomised trial. Ann Oncol 2002;13:102-106.
36. RADFORD JA, ROHATINER AZ, RYDER WD, et al. ChlVPP/ EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin's disease. J Clin Oncol 2002;20:2988-2994.
37. DIEHL V, FRANKLIN J, HASENCLEVER D, et al. BEACOPP: a new regimen for advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group. Ann Oncol 1998;9:67-71.
38. DIEHL V, SIEBER M, RUFFER U, et al. BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group. Ann Oncol 1997;8:143-148.
39. SIEBER M, BREDENFELD H, JOSTING A, et al. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003;21:1734-1739.
40. FEDERICO M, BELLEI M, BRICE P, et al. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. J Clin Oncol 2003;21:2320-2325.
41. BREDENFELD H, FRANKLIN J, NOGOVA L, et al. Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: a report of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2004;22:2424-2429.
42. BEHRINGER K, JOSTING A, SCHILLER P, et al. Solid tumors in patients treated for Hodgkin's disease: a report from the German Hodgkin Lymphoma Study Group. Ann Oncol 2004;15:1079-1085.
43. LÖFFLER M, BROSTEANU O, HASENCLEVER D, et al. Meta-Analysis of Chemotherapy versus combined modality treatment trials in Hodgkin's Disease. J Clin Oncol 1998;16:818-829.
44. ALEMAN BM, RAEMAEKERS JM, TIRELLI U, et al. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med 2003;348:2396-2406.
45. BIERMAN P, BAGIN R, JAGANNATH S, et al. High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients. Ann Oncol 1993;4:767-773.
46. REECE D, CONNORS J, SPINELLI J, et al. Intensive therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood 1994;83:1193-1199.
47. LINCH D, WINFIELD D, GOLDSTONE A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993;341:1051-1054.
48. SCHMITZ N, PFISTNER B, SEXTRO M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002;359:2065-2071.
49. JOSTING A, FRANKLIN J, MAY M, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol 2002;20:221-230.
50. JOSTING A, RUDOLPH C, REISER M, et al. Time-intensified Dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol 2002;13:1628-1635.
51. GLOSSMANN JP, JOSTING A, PFISTNER B, et al. A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's disease (HD-R2). Ann Hematol 2002;81:424-429.
52. SUREDA A, SCHMITZ N. Allogeneic stem cell transplantation after reduced-intensity conditioning in lymphoid malignancies. Ann Hematol 2003;82:1-13.
53. SCHMITZ N, SUREDA A, ROBINSON S. Allogeneic transplantation of hematopoietic stem cells after nonmyeloablative conditioning for Hodgkin's disease: indications and results. Semin Oncol 2004;31:27-32.
54. EKSTRAND BC, LUCAS JB, HORWITZ SM, et al. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood 2003;101:4285-4289.
55. REHWALD U, SCHULZ H, REISER M, et al. Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood 2003;101:420-424.
56. BALLOVA V, RUEFFER JU, HAVERKAMP H, et al. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol 2005;16:124-131.
57. DONNEZ J, DOLMANS MM, DEMYLLE D, et al. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet 2004;364:1405-1410.
58. BEHRINGER K, BREUER K, REINEKE T, et al. Secondary Amenorrhoea after Hodgkin's Disease is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin Lymphoma Study Group (GHSG). (in press).
59. KREUSER ED, FELSENBERG D, BEHLES C, et al. Long-term gonadal dysfunction and its impact on bone mineralization in patients following COPP/ABVD chemotherapy for Hodgkin's disease. Ann Oncol 1992;3(Suppl. 4):105-110.
60. BLUMENFELD Z, DANN E, AVIVI I, et al. Fertility after treatment for Hodgkin's disease. Ann Oncol 2002;13(Suppl. 1):138-147.
61. BORCHMANN P, SCHNELL R, FUSS I, et al. Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma. Blood 2002;100:3101-3107.
62. SCHNELL R, DIETLEIN M, STAAK O, et al. Non-myeloablative radio-immunotherapy with a iodine-131-tagged anti-CD30 antibody (131I-Ki-4) in patients with refractory Hodgkin's lymphoma. Blood 2002;100:762a.
63. BORCHMANN P, TREML JF, HANSEN H, et al. The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma. Blood 2003;102:3737-3742.